|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2011-4-18
|
|
pubmed:abstractText |
Sphingosine 1-phosphate (S1P) is an important mediator of cancer cell growth and proliferation. Production of S1P is catalyzed by sphingosine kinase 1 (SphK). Safingol, (l-threo-dihydrosphingosine) is a putative inhibitor of SphK. We conducted a phase I trial of safingol (S) alone and in combination with cisplatin (C).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
©2011 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2484-92
|
|
pubmed:meshHeading |
pubmed-meshheading:21257722-Adult,
pubmed-meshheading:21257722-Aged,
pubmed-meshheading:21257722-Aged, 80 and over,
pubmed-meshheading:21257722-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21257722-Area Under Curve,
pubmed-meshheading:21257722-Cisplatin,
pubmed-meshheading:21257722-Dose-Response Relationship, Drug,
pubmed-meshheading:21257722-Drug Administration Schedule,
pubmed-meshheading:21257722-Fatigue,
pubmed-meshheading:21257722-Female,
pubmed-meshheading:21257722-Humans,
pubmed-meshheading:21257722-Lymphopenia,
pubmed-meshheading:21257722-Lysophospholipids,
pubmed-meshheading:21257722-Male,
pubmed-meshheading:21257722-Metabolic Clearance Rate,
pubmed-meshheading:21257722-Middle Aged,
pubmed-meshheading:21257722-Neoplasms,
pubmed-meshheading:21257722-Phosphotransferases (Alcohol Group Acceptor),
pubmed-meshheading:21257722-Sphingosine,
pubmed-meshheading:21257722-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors.
|
|
pubmed:affiliation |
Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
